Jazz Long Term Debt Total vs Accounts Payable Analysis

JAZZ Stock  USD 122.99  0.61  0.49%   
Jazz Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Jazz Pharmaceuticals PLC recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jazz Pharmaceuticals PLC is a good investment. Please check the relationship between Jazz Pharmaceuticals Long Term Debt Total and its Accounts Payable accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Long Term Debt Total vs Accounts Payable

Long Term Debt Total vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jazz Pharmaceuticals PLC Long Term Debt Total account and Accounts Payable. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Jazz Pharmaceuticals' Long Term Debt Total and Accounts Payable is 0.98. Overlapping area represents the amount of variation of Long Term Debt Total that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Jazz Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Jazz Pharmaceuticals' Long Term Debt Total and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt Total of Jazz Pharmaceuticals PLC are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Long Term Debt Total i.e., Jazz Pharmaceuticals' Long Term Debt Total and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.98
Relationship DirectionPositive 
Relationship StrengthVery Strong

Long Term Debt Total

Accounts Payable

An accounting item on the balance sheet that represents Jazz Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Jazz Pharmaceuticals PLC are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Jazz Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jazz Pharmaceuticals PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
At this time, Jazz Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.39 in 2024, despite the fact that Tax Provision is likely to grow to (177.5 M).
 2021 2022 2023 2024 (projected)
Gross Profit2.7B3.1B3.4B3.6B
Total Revenue3.1B3.7B3.8B4.0B

Jazz Pharmaceuticals fundamental ratios Correlations

0.430.340.380.320.530.360.410.30.40.350.460.420.270.320.350.40.410.490.070.360.220.260.530.360.36
0.430.980.970.90.910.940.790.960.750.960.710.990.870.650.980.610.980.990.110.980.890.940.980.980.95
0.340.980.980.910.810.950.70.990.610.970.690.970.850.591.00.510.960.96-0.040.990.940.960.941.00.9
0.380.970.980.940.830.90.690.950.640.980.760.950.890.610.970.60.980.960.020.960.890.970.950.980.9
0.320.90.910.940.790.830.540.850.610.920.860.850.880.450.870.710.950.880.090.860.770.980.90.90.87
0.530.910.810.830.790.80.860.780.930.810.690.880.80.690.80.760.890.910.440.80.680.790.950.820.95
0.360.940.950.90.830.80.70.960.650.920.570.970.80.440.950.40.890.94-0.090.960.890.870.890.960.87
0.410.790.70.690.540.860.70.730.860.680.390.790.680.820.720.510.740.780.430.730.660.610.80.710.85
0.30.960.990.950.850.780.960.730.590.960.570.980.80.590.990.40.920.95-0.080.990.960.910.90.990.87
0.40.750.610.640.610.930.650.860.590.610.540.720.710.610.610.720.740.760.60.610.440.60.80.630.87
0.350.960.970.980.920.810.920.680.960.610.710.950.90.550.970.520.960.95-0.060.960.920.950.930.980.9
0.460.710.690.760.860.690.570.390.570.540.710.630.750.460.650.870.810.720.170.630.50.780.780.680.7
0.420.990.970.950.850.880.970.790.980.720.950.630.830.610.980.50.950.990.030.980.910.90.960.980.92
0.270.870.850.890.880.80.80.680.80.710.90.750.830.510.830.650.920.860.150.820.70.850.870.850.91
0.320.650.590.610.450.690.440.820.590.610.550.460.610.510.610.560.640.620.420.610.60.530.680.590.66
0.350.981.00.970.870.80.950.720.990.610.970.650.980.830.610.470.950.96-0.071.00.950.930.931.00.88
0.40.610.510.60.710.760.40.510.40.720.520.870.50.650.560.470.70.590.640.450.30.640.710.50.71
0.410.980.960.980.950.890.890.740.920.740.960.810.950.920.640.950.70.970.140.940.830.950.980.960.95
0.490.990.960.960.880.910.940.780.950.760.950.720.990.860.620.960.590.970.080.970.860.910.980.970.94
0.070.11-0.040.020.090.44-0.090.43-0.080.6-0.060.170.030.150.42-0.070.640.140.08-0.08-0.180.060.21-0.050.33
0.360.980.990.960.860.80.960.730.990.610.960.630.980.820.611.00.450.940.97-0.080.950.920.931.00.88
0.220.890.940.890.770.680.890.660.960.440.920.50.910.70.60.950.30.830.86-0.180.950.870.820.940.77
0.260.940.960.970.980.790.870.610.910.60.950.780.90.850.530.930.640.950.910.060.920.870.910.950.89
0.530.980.940.950.90.950.890.80.90.80.930.780.960.870.680.930.710.980.980.210.930.820.910.940.96
0.360.981.00.980.90.820.960.710.990.630.980.680.980.850.591.00.50.960.97-0.051.00.940.950.940.9
0.360.950.90.90.870.950.870.850.870.870.90.70.920.910.660.880.710.950.940.330.880.770.890.960.9
Click cells to compare fundamentals

Jazz Pharmaceuticals Account Relationship Matchups

Jazz Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding57.6M56.5M59.7M62.5M72.1M51.5M
Total Assets5.5B6.5B12.3B10.8B11.4B12.0B
Short Long Term Debt Total1.8B2.2B6.1B5.8B5.8B6.1B
Other Current Liab278.8M338.3M650.5M787.3M774.5M813.2M
Total Current Liabilities364.5M653.7M809.3M933.2M1.5B1.6B
Total Stockholder Equity3.1B3.7B4.0B3.1B3.7B3.9B
Other Liab337.7M233.9M1.4B1.0B1.2B1.3B
Property Plant And Equipment Net270.9M257.1M343.4M301.4M235.0M119.6M
Net Debt1.1B1.2B5.5B4.9B4.3B4.5B
Retained Earnings1.1B1.2B830.2M733.6M878.7M922.6M
Accounts Payable47.5M26.9M100.3M90.8M102.8M107.9M
Cash637.3M1.1B591.4M881.5M1.5B1.6B
Non Current Assets Total3.9B3.7B9.7B8.2B8.0B8.4B
Non Currrent Assets Other47.9M25.7M40.8M58.9M69.2M72.7M
Other Assets272.2M415.0M363.9M435.1M171.5M136.8M
Long Term Debt1.6B1.8B6.0B5.7B5.1B5.4B
Cash And Short Term Investments1.1B2.1B591.4M881.5M1.6B1.7B
Net Receivables356.0M396.5M563.4M651.5M705.8M741.1M
Good Will920.0M958.3M1.8B1.7B1.8B1.8B
Short Term Investments515M440M1.1B30M120M147.5M
Liabilities And Stockholders Equity5.5B6.5B12.3B10.8B11.4B12.0B
Non Current Liabilities Total2.1B2.2B7.5B6.8B6.1B6.4B
Inventory78.6M95.4M1.1B714.1M597.0M626.9M
Other Current Assets78.9M214.9M383.8M359.1M506.3M531.6M
Other Stockholder Equity2.3B2.6B3.5B3.5B3.7B3.9B
Total Liab2.4B2.9B8.3B7.7B7.7B8.0B
Property Plant And Equipment Gross270.9M257.1M343.4M301.4M368.3M386.8M
Total Current Assets1.6B2.8B2.6B2.6B3.4B3.6B
Accumulated Other Comprehensive Income(223.4M)(134.4M)(400.4M)(1.1B)(842.1M)(800.0M)
Intangible Assets2.4B2.2B7.2B5.8B5.4B5.7B
Property Plant Equipment270.9M127.9M343.4M301.4M346.6M363.9M
Current Deferred Revenue4.7M2.5M2.1M463K116.1M121.9M
Net Tangible Assets(250.0M)648.7M(5.0B)(4.3B)(3.9B)(3.7B)
Capital Surpluse2.3B2.6B3.5B3.5B4.0B2.2B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.